



Test Report/ Certificate of Analysis

Date of Report Nov 4, 2025

To: 1stPharma Peptides

From: AxisPharm, LLC

Certificate ID Number: 04Nov2025-19

Results reported by: Lab Technician
Ning Yang

Review/Approved by: 
QA Director
Dawei Yue

Sample Received: Date: 10/30/2025
Receiving Condition: ☒ Acceptable ☐ Other: _____
Storage Condition: ☐ Room temperature ☐ -20°C ☒ -80°C
☐ Other: _____


Method(s): Sample Name: Tirzepatide; Batch: TRIZ-60-308-25, Label
mg Claim: 60mg; BBD: 11/04/2027
LCMS

Procedure(s): Laboratory Activity Date: 11/03/2025

Results:



Test Report/ Certificate of Analysis



Sample Name	Net Weight Measured	MW (g/mol)	Detected	UV Purity (%)
Tirzepatide 60mg	57.4 mg	4813.53	2411.0 [M+2H], 1607.0 [M+3H]	>99.4%

Salts and sugars that serves as fillers in injectables are not considered as impurities.

Conclusion: The product comes with Tirzepatide 57.4 mg with purity >99.4%.